The common stock is listed on the Nasdaq Global Market

avis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a registered offering by Nurix Therapeutics, Inc. of 24,485,799 shares of common stock at $10.21 per share for total gross proceeds of approximately $250 million. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Savannah J. Dowling and Grace Yongxi Pan. Partner Ethan R. Goldman and associate Michael Hsieh provided tax advice. Partner David R. Bauer and associates Hannah Coleman and Daniella Martino provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post